Jon Coriell, MBA’s Post

AZD0901 (formerly known as CMG901) has recently initiated dosing in its first patient for a Phase 3 clinical trial (NCT06346392), marking it as the second claudin 18.2-targeting drug to progress to this phase following Transcenta's osemitamab. Unlike osemitamab, which is targeted for 1st line Gastric/Gastroesophageal Junction cancer treatment in combination with nivolumab and chemotherapy, AZD0901 is uniquely positioned in the 2nd line setting and is administered as a monotherapy. Interestingly, South Korea is missing among the known clinical sites, even though it's a gastric cancer trial.

Alligator Bioscience AB has announced positive 18-month follow-up data from the OPTIMIZE-1 Phase 2 study of the company’s lead asset mitazalimab in 1st line metastatic pancreatic cancer. The open-label, multi-center study assessed the safety and efficacy of anti-CD40 mitazalimab in combination with standard of care chemotherapy mFOLFIRINOX, in previously untreated, chemotherapy naïve pancreatic cancer patients. The data demonstrated 18-month survival rate of 36.2% in patients treated with mitazalimab in combination with mFOLFIRINOX, compared to 18.6% reported with FOLFIRINOX alone. Alligator is continuing its preparations for the global Phase 3 registration study to evaluate mitazalimab in pancreatic cancer and the company remains on track to initiate the study in 2025.  https://lnkd.in/dVgcV5Fr

#Tarlatamab introduces T cells to cancer A bispecific antibody called Imdelltra (tarlatamab) that brings cancer cells and T cells into close proximity has been approved by the FDA for an aggressive type of #lungcancer. The drug binds to delta-like ligand 3, a molecule that is found on the surface of almost all small-cell lung cancer cells, but is not expressed on the surface of healthy cells. It simultaneously binds to the CD3 receptor on the T cell, bringing it close enough to the cancer cell to launch an attack. https://lnkd.in/gGeimjq8

FDA Approval: New treatment for non-small cell lung cancer (NSCLC) that is advanced/metastatic, is positive for the EGFR (epidermal growth factor receptor) mutations Exon 19 or Exon 21 L858R, and has progressed after prior use of an EGFR targeted therapy. On September 19, 2024, the FDA issued a new approval for the targeted therapy drug Rybrevant (amivantamab-vmjw) in combination with the existing combination chemotherapy treatment, Paraplatin (carboplatin) + Alimta (pemetrexed). This approval marks a critical advancement for EGFR-positive lung cancer patients, opening doors to more effective treatment strategies. Learn more ➡️ https://lnkd.in/eMVnesdR #FDAApproval #LungCancerTreatment #EGFRPositive #OncologyInnovation #PrecisionMedicine

Thanks FirstWord Pharma for covering our upcoming #ASCO24 data: AffyImmune Therapeutics said Thursday its autologous CAR-T cell therapy AIC100 is the first to achieve a complete response in a patient with a solid tumour. The Phase I trial data, shared ahead of a presentation at the American Society of Clinical Oncology (ASCO) annual meeting, suggest the therapy could be a tolerable and efficacious option to treat thyroid cancer. The study is enrolling patients with either anaplastic thyroid cancer (ATC) or poorly differentiated thyroid cancer (PDTC) to receive one of three dose levels of AIC100 – either 1x 107, 1 x 108, or 5 x 108 cells – which is an ICAM-1 targeting and affinity-tuned LFA-1 binder CAR-T. Read the article by Elizabeth Eaton: https://lnkd.in/eEn5crhA

As reported in the Financial Times today AstraZeneca unveiled successes in the #treatment of #lung #cancer on Monday, with its leading drug slowing progression of the disease at an early stage. Its best-selling #Tagrisso drug showed a “statistically significant and highly clinically meaningful” improvement in preventing the progression of a version of the most common form of the disease, the company said. The trial will continue to assess overall survival rates of the treatment, with current data showing a “favourable trend”. The Tagrisso trial was designed for patients with non-small cell lung cancer, the most common form, who have a so-called epidermal growth factor receptor mutation, which is prevalent in 10 to 15 per cent of cases in Europe and the US and up to 40 per cent in Asia. “Sometimes people are too nihilistic about lung cancer. If you diagnose it early, you can make a difference to this disease. These data reinforce that message,” said Susan Galbraith, executive vice-president of #oncology R&D at AstraZeneca. AstraZeneca also announced on Monday that the drug had been approved to be used alongside chemotherapy in the US to treat the same form of lung cancer at an advanced stage, where it extended progression-free survival by almost nine months. For more of the lastest news and content on lung cancer sign up for a free subscription to EMJ Oncology. https://lnkd.in/efTbyQCj #LungCancer #ClinicalTrails #Oncology #Respiratory #EMJInspire #EuropeanMedicalJournal #AmericanMedicalJournal #AMJ

Join this week's Cholangiocarcinoma Foundation Educational Webinar: A clinical trial for a potential new tHER2apy for biliary tract cancers with James J Harding, MD, with Memorial Sloan Kettering Cancer Center and Phillip Garfin, MD, PhD from Jazz Pharmaceuticals. This presentation will cover the Human Epidermal Growth Factor Receptor-2 (HER2) protein and its role in cancer, with a focus on biliary tract cancers. Presentation Highlights: 🗣 Discussion on designing cancer treatments targeting HER2 💊 Introduction to Zanidatamab as a potential treatment for HER2-positive cancers 📊 Insights from a recent clinical study on the safety and efficacy of Zanidatamab in BTC treatment Register here: https://lnkd.in/gEEdN-64

🎗 𝗕𝗶𝗼𝗡𝗧𝗲𝗰𝗵'𝘀 𝗛𝟭 𝗢𝗻𝗰𝗼𝗹𝗼𝗴𝘆 𝗠𝗶𝗹𝗲𝘀𝘁𝗼𝗻𝗲𝘀 📣 We are advancing our oncology pipeline with mRNA as the centerpiece of our toolbox. In the first half of 2024, we presented encouraging data from our investigational mRNA-based cancer therapies, including BNT111 and BNT122. Additionally, we have progressed the development of immunomodulatory candidates, such as BNT327, which we believe are well-suited for combination therapies. We have continued to execute our combination therapy strategy by successfully initiating a trial evaluating the antibody candidate BNT327 in combination with the investigational ADC BNT325. 🌟🧬 More news from H1/2024 in our PR (incl. forward-looking statements): https://lnkd.in/edJXDHc9 #BioNTech #mRNA #CancerTherapy #Oncology

SDBN Feed: Halozyme Announces Roche Receives European Commission Approval of Tecentriq® SC with ENHANZE® Representing the EU’s First Subcutaneous PD-(L)1 Cancer Immunotherapy for Multiple Cancer Types https://lnkd.in/g7GHQN7G Reduces treatment time by approximately 80% compared to standard intravenous (IV) infusion Subcutaneous (SC) injection offers the potential for a faster, more convenient alternative to IV infusion and is preferred by patients and healthcare practitioners1 [...]

Let's talk about solid tumours...   One of the key challenges facing the oncology field is finding the perfect target for treating solid tumours. This is because almost all tumour targets can also be found on healthy cells.   The result? It's very difficult to find the "perfect" target antigen in solid tumours that does not cause any on-target off-tumour toxicity.   This is where Bi-Cygni® comes in. Our solution to this tricky problem in solid tumours is to use our unique platform to help design first-in-class antibody-drug conjugates (ADCs) that can selectively target dual antigen binding events in cancer cells while leaving "non-target cells" unharmed.   We've already used this approach to create a promising Bi-Cygni® ADC for ovarian cancer, BVX002, and we hope to apply it to many more solid tumour indications in the future.   To learn more about our pipeline and our science, check out our website: https://lnkd.in/emX6WskJ   #ADC #therapeutics #oncologyresearch #solidtumors #antibodies #biotherapeutics #ovariancancer